Condition
Thrombotic Thrombocytopenic Purpura (TTP) clinical trials and research
As of November 12, 2026, Find a Trial lists 5 Thrombotic Thrombocytopenic Purpura (TTP) clinical trials that are recruiting, at sites in 5 countries (most in France (2), Germany (2), Poland (1)). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 5Countries
Newest Thrombotic Thrombocytopenic Purpura (TTP) clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| cTTP patients treated with recombinant ADAMTS13: what happened after the early access program | — | Cologne, North Rhine-Westphalia and 7 other locations | Recruiting | Feb 24, 2026 |
| Adzynma in people with congenital TTP: a look at safety and antibody risk | — | Vienna and 6 other locations | Recruiting | Jan 20, 2026 |
| Long-term outcomes for people with immune TTP in the French national TMA cohort | — | Paris | Recruiting | Oct 3, 2025 |
| Understanding the immune response in Thrombotic Thrombocytopenic Purpura | — | Rouen | Recruiting | Apr 25, 2025 |
| Survey of a treatment for congenital thrombotic thrombocytopenic purpura | — | Tokyo, Tokyo | Recruiting | Jun 4, 2024 |
All recruiting trials (5)
-
cTTP patients treated with recombinant ADAMTS13: what happened after the early access program
This study looks at people with congenital TTP who received recombinant ADAMTS13 to see how treatment changes their health before and after use.
-
Adzynma in people with congenital TTP: a look at safety and antibody risk
This study checks whether people with congenital TTP who have already received Adzynma develop neutralizing antibodies against Adzynma within six months of starting treatment.
-
Long-term outcomes for people with immune TTP in the French national TMA cohort
This project uses past medical records to see long-term health outcomes and complications in people in France who had immune thrombotic thrombocytopenic purpura (iTTP).
-
Understanding the immune response in Thrombotic Thrombocytopenic Purpura
This study is trying to understand how certain immune cells behave in people with Thrombotic Thrombocytopenic Purpura to see if they can help predict relapses and improve treatment.
-
Survey of a treatment for congenital thrombotic thrombocytopenic purpura
This study is testing a new treatment called recombinant ADAMTS13 to see if it helps people with congenital thrombotic thrombocytopenic purpura feel better and stay healthy over 18 months.
Related topics
Quick answers
How many Thrombotic Thrombocytopenic Purpura (TTP) clinical trials are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 5 countries. The most sites are in France (2 trials), Germany (2 trials), Poland (1 trial), Austria (1 trial), Japan (1 trial). Each study page lists its sites and which ones are recruiting.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.